SCHEMBL808070

SCHEMBL808070

CNNc1cnc2ccc(Br)cc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.39
PDGFRA P16234 5/20 0.39
HTT P42858 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
PABPC1 P11940 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
EGFR P00533 2/20 0.35
MEN1 O00255 1/20 0.35
ERBB2 P04626 1/20 0.35
KMT2A Q03164 1/20 0.35
TNK2 Q07912 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
PIK3R1 P27986 1/20 0.35
PIK3CA P42336 1/20 0.35
TSHR P16473 1/20 0.35
BACE1 P56817 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2621736 0.89 PDGFRB (0.41) PDGFRBPDGFRAHTTCYP1A2CYP2C19
SCHEMBL780200 0.82 PABPC1 (0.42) PDGFRBPDGFRAHTTCYP1A2CYP2C19
SCHEMBL796733 0.81 PABPC1 (0.41) PDGFRBPDGFRAHTTCYP1A2CYP2C19
SCHEMBL30359519 0.81 PABPC1 (0.41) PDGFRBPDGFRAHTTCYP1A2CYP2C19
SCHEMBL2621754 0.80 HTT (0.49) PDGFRBPDGFRAHTTCYP1A2CYP2C19
SCHEMBL23246999 0.79 EGFR (0.43) PDGFRBPDGFRAHTTKDM4EHSP90AA1
SCHEMBL26654324 0.77 BACE1 (0.50) HTTCYP1A2CYP2C19PABPC1KDM4E
SCHEMBL797194 0.74 ABL1 (0.51) PDGFRBPDGFRACYP1A2CYP2C19
SCHEMBL1639504 0.74 HTT (0.41) HTTCYP1A2CYP2C19PABPC1KDM4E
SCHEMBL2621734 0.74 EGFR (0.47) CYP2C19KDM4EEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 WO disclosed